

Lulu Chu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10474881/publications.pdf>

Version: 2024-02-01

14
papers

357
citations

1040056

9
h-index

1125743

13
g-index

14
all docs

14
docs citations

14
times ranked

555
citing authors

#	ARTICLE	IF	CITATIONS
1	Evaluation of Combination Strategies for the A2AR Inhibitor AZD4635 Across Tumor Microenvironment Conditions via a Systems Pharmacology Model. <i>Frontiers in Immunology</i> , 2021, 12, 617316.	4.8	10
2	Chimeric Antigen Receptor T Cell Therapies: A Review of Cellular Kineticâ€Pharmacodynamic Modeling Approaches. <i>Journal of Clinical Pharmacology</i> , 2020, 60, S147-S159.	2.0	28
3	Dose dependence of treatment-related adverse events for immune checkpoint inhibitor therapies: a model-based meta-analysis. <i>OncImmunity</i> , 2020, 9, 1748982.	4.6	23
4	Differentiating the Sodiumâ€Glucose Cotransporter 1 Inhibition Capacity of Canagliflozin vs. Dapagliflozin and Empagliflozin Using Quantitative Systems Pharmacology Modeling. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2020, 9, 222-229.	2.5	19
5	Comparison of the urinary glucose excretion contributions of SGLT2 and SGLT1: A quantitative systems pharmacology analysis in healthy individuals and patients with type 2 diabetes treated with SGLT2 inhibitors. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2684-2693.	4.4	28
6	Quantitative Systems Pharmacology: An Exemplar Modelâ€Building Workflow With Applications in Cardiovascular, Metabolic, and Oncology Drug Development. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2019, 8, 380-395.	2.5	33
7	Quantitative Mechanistic Modeling in Support of Pharmacological Therapeutics Development in Immuno-Oncology. <i>Frontiers in Immunology</i> , 2019, 10, 924.	4.8	31
8	Na ⁺ microdomains and sparks: Role in cardiac excitation-contraction coupling and arrhythmias in ankyrin-B deficiency. <i>Journal of Molecular and Cellular Cardiology</i> , 2019, 128, 145-157.	1.9	10
9	Radiation and PD-(L)1 treatment combinations: immune response and dose optimization via a predictive systems model. , 2018, 6, 17.		81
10	Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data. <i>American Journal of Physiology - Renal Physiology</i> , 2018, 315, F1295-F1306.	2.7	46
11	Abstract 2098: Quantitative modeling as a systematic approach for drug combination evaluation in immuno-oncology (IO). <i>Cancer Research</i> , 2018, 78, 2098-2098.	0.9	2
12	Drug-disease modeling in the pharmaceutical industry - where mechanistic systems pharmacology and statistical pharmacometrics meet. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 109, S39-S46.	4.0	25
13	Model-based meta-analysis of safety for immune checkpoint inhibitor combinations and monotherapy.. <i>Journal of Clinical Oncology</i> , 2017, 35, 89-89.	1.6	1
14	Modeling Na ⁺ -Ca ²⁺ exchange in the heart: Allosteric activation, spatial localization, sparks and excitation-contraction coupling. <i>Journal of Molecular and Cellular Cardiology</i> , 2016, 99, 174-187.	1.9	20